<DOC>
	<DOCNO>NCT00478816</DOCNO>
	<brief_summary>Valuate immune response reactogenicity H5N1 vaccination prim population ( H5N3 adjuvanted non-adjuvanted vaccine ) compare immunologically naïve subject</brief_summary>
	<brief_title>Safety Immunogenicity Two Doses H5N1 Influenza Vaccine Adults Unprimed Primed With Adjuvanted Non-adjuvanted Influenza Vaccines</brief_title>
	<detailed_description />
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Influenza Birds</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>1 . Subjects age 18 65 year age , mentally competent , sign informed consent form receive detailed explanation study protocol ; 2 . In good health determine : 1. medical history , 2. physical examination , 3. clinical judgment Investigator ; 3 . Subjects prim group previously receive least two dos H5N3 vaccine ; 4 . Able understand comply study procedure complete study diary , contact , available study visit . 1 . Receipt another investigational agent within 4 week , completion safety followup period another study , whichever longer , prior enrollment unwilling refuse participation another clinical study end study ; 2 . Subjects experience acute disease infection require systemic antibiotic antiviral therapy ( chronic antibiotic therapy urinary tract prophylaxis acceptable ) within past 7 day ; 3 . Subjects experience fever ( defined axillary temperature ≥38.0°C ) within 3 day prior Visit 1 ; 4 . Subjects pregnant breastfeeding ; 5 . Females childbearing potential refuse use acceptable method birth control duration study . Adequate contraception define hormonal ( e.g. , oral , injection , transdermal patch , implant , cervical ring ) , barrier ( e.g. , condom spermicide diaphragm spermicide ) , intrauterine device ( e.g. , IUD ) , monogamous relationship vasectomize partner vasectomize 6 month prior subject 's study entry ; 6 . Subjects serious disease , : 1. cancer , 2. autoimmune disease ( include rheumatoid arthritis ) , 3. diabetes mellitus , 4. chronic pulmonary disease , 5. acute progressive hepatic disease , 6. acute progressive renal disease ; 7 . Subjects surgery plan study period ; 8 . Subjects bleed diathesis ; 9 . Subjects hypersensitivity egg , chicken protein , chicken feather , influenza viral protein , neomycin polymyxin component study vaccine ; 10 . Subjects history neurological symptom sign , anaphylactic shock follow administration vaccine ; 11 . Subjects know suspected impairment/alteration immune function , example , result : 1. receipt immunosuppressive therapy ( corticosteroid therapy cancer chemotherapy ) , 2. receipt immunostimulants , 3. receipt parenteral immunoglobulin preparation , blood product , and/or plasma derivative within 3 month prior Visit 1 plan full length study , 4. high risk develop immunocompromising disease ; 12 . Receipt another vaccine within 3 week prior Visit 1 plan vaccination within 3 week follow last study vaccination ; 13 . Subjects history ( current ) drug alcohol abuse investigator 's opinion would interfere safety subject evaluation study objective ; 14 . Subjects condition , , opinion Investigator , might interfere evaluation study objective .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2012</verification_date>
	<keyword>Bird flu</keyword>
	<keyword>influenza vaccine</keyword>
	<keyword>prepandemic vaccine</keyword>
</DOC>